PARP16
Mono [ADP-ribose] polymerase PARP16
Protein Summary
Intracellular mono-ADP-ribosyltransferase that may play a role in different processes through the mono-ADP-ribosylation of proteins involved in those processes (PubMed:23103912, PubMed:22701565). May play a role in the unfolded protein response (UPR), by ADP-ribosylating and activating EIF2AK3 and ERN1, two important UPR effectors (PubMed:23103912). May also mediate mono-ADP-ribosylation of karyopherin KPNB1 a nuclear import factor (PubMed:22701565). May not modify proteins on arginine, cysteine or glutamate residues compared to other mono-ADP-ribosyltransferases (PubMed:22701565).
- ENST00000261888
- ENSP00000261888
- ENSG00000138617
- ENST00000444347
- ENSP00000396118
- ENST00000649807
- ENSP00000496935
- ARTD15
- C15orf30
- ARTD15
- pART15
- C15orf30
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor binding site profile | 0.79 | ||
histone modification site profile | 0.78 | ||
microRNA | 0.72 | ||
disease perturbation | 0.68 | ||
small molecule perturbation | 0.68 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 17.11 (req: < 5)
Gene RIFs: 4 (req: <= 3)
Antibodies: 151 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 17.11 (req: >= 5)
Gene RIFs: 4 (req: > 3)
Antibodies: 151 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 11
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 1
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0